- Home
- KIM vs DVA Comparison
KIM vs DVA Comparison
Compare KIM & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIM | DVA |
|---|---|---|
| Founded | 1958 | 1994 |
| Country | United States | United States |
| Employees | 710 | N/A |
| Industry | Real Estate Investment Trusts | Misc Health and Biotechnology Services |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 13.5B |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | KIM | DVA |
|---|---|---|
| Price | $25.76 | $214.33 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 4 |
| Target Price | $25.00 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 5.0M | 660.6K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.40% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.87 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $3.31 | $3.85 |
| Revenue Next Year | $3.57 | $3.07 |
| P/E Ratio | ★ $27.76 | $74.31 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $19.76 | $101.00 |
| 52 Week High | $26.08 | $215.33 |
Technical Indicators
Market Signals| Indicator | KIM | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 65.42 | 72.97 |
| Support Level | $23.21 | $189.09 |
| Resistance Level | $26.08 | N/A |
| Average True Range (ATR) | 0.49 | 5.18 |
| MACD | 0.04 | 0.17 |
| Stochastic Oscillator | 86.07 | 98.21 |
Price Performance
Historical ComparisonAbout KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 565 shopping centers throughout major markets in the US, representing roughly 100 million square feet.
About DVA DaVita Inc.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.